CD322抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD322 mouse mAb against NIH/3T3 (1), Ramos (2), and HepG2 (3) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD322 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD322 mouse mAb (green) and negative control (red).    

  
  

CD322. also known as Junctional Adhesion Molecule-C (JAM-C), is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It features two extracellular V-type immunoglobulin (Ig) domains and mediates cell-cell adhesion through homophilic or heterophilic interactions. Primarily expressed on endothelial cells, epithelial cells, platelets, and immune cells, JAM-C plays critical roles in maintaining vascular permeability, leukocyte transmigration, and barrier integrity. It regulates inflammatory responses by facilitating leukocyte recruitment to sites of injury or infection and modulates angiogenesis through interactions with integrins or other adhesion receptors.

CD322 antibodies are tools for studying JAM-C's biological functions and therapeutic potential. In research, these antibodies block JAM-C activity to investigate its involvement in inflammatory diseases (e.g., rheumatoid arthritis, atherosclerosis), cancer progression (e.g., tumor angiogenesis, metastasis), and thrombotic disorders. Preclinical studies suggest that inhibiting JAM-C with antibodies may reduce pathological leukocyte infiltration or disrupt tumor vasculature. However, its dual roles in pro-inflammatory and barrier-protective pathways require context-specific therapeutic strategies. CD322 antibodies are also used in flow cytometry and immunohistochemistry to analyze JAM-C expression patterns in health and disease. Ongoing research aims to refine antibody specificity and evaluate clinical applications, particularly in targeting JAM-C-associated pathological processes.